Trial Profile
Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Limited Reinfusion of CD34+ Cells
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Angiotensin-1-7 (Primary)
- Indications Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms TXA127-PBSC
- Sponsors Tarix Pharmaceuticals
- 07 Dec 2020 Status changed from active, no longer recruiting to discontinued.
- 08 Oct 2020 Planned End Date changed from 1 Sep 2020 to 1 Mar 2022.
- 08 Oct 2020 Planned primary completion date changed from 1 Jun 2020 to 1 Dec 2021.